Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Substitutive therapies in sepsis and acute renale failure].
Mariano F, Hollò Z, Damiani D, Cogno C, Torazza MC, Maffei S, Risso D, Vacca M, Della Valle A, Triolo G. Mariano F, et al. Among authors: cogno c. G Ital Nefrol. 2006 May-Jun;23 Suppl 36:S87-93. G Ital Nefrol. 2006. PMID: 17068735 Review. Italian.
Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
Boero R, Rollino C, Massara C, Vagelli G, Gonella M, Berto IM, Bajardi P, Perosa P, Malcangi U, Giorgi MP, Ghezzi PM, Borzumati M, Baroni AM, Cogno C, Triolo G, Angelini D, Antonelli A, Quarello F. Boero R, et al. Among authors: cogno c. J Nephrol. 2001 Jan-Feb;14(1):15-8. J Nephrol. 2001. PMID: 11281338 Clinical Trial.
Impact of donor age in kidney transplantation.
Segoloni GP, Messina M, Triolo G, Cogno C, Amoroso A, Vercellone A. Segoloni GP, et al. Among authors: cogno c. Transplant Proc. 1991 Oct;23(5):2620-1. Transplant Proc. 1991. PMID: 1926507 Clinical Trial. No abstract available.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.